Madison Avenue Partners’s Ovid Therapeutics OVID Stock Holding History

Madison Avenue Partners’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,311,362	Closed	-$433K	–	25
2025 Q2	$433K	Sell	1,311,362 -1,154,261	-47%	-$348K	0.03%	26
2025 Q1	$769K	Sell	2,465,623 -1,257,004	-34%	-$773K	0.07%	19
2024 Q4	$3.48M	Sell	3,722,627 -394,146	-10%	-$441K	0.37%	13
2024 Q3	$4.86M	Buy	4,116,773 +34,673	+0.8%	+$36.2K	0.45%	19
2024 Q2	$3.14M	Buy	4,082,100 +433,591	+12%	+$1.21M	0.4%	18
2024 Q1	$11.1M	Hold	3,648,509	–	–	1.8%	11
2023 Q4	$11.7M	Hold	3,648,509	–	–	1.66%	11
2023 Q3	$14M	Buy	3,648,509 +340,904	+10%	+$1.23M	1.99%	9
2023 Q2	$10.8M	Buy	3,307,605 +203,002	+7%	+$689K	2.37%	10
2023 Q1	$8.01M	Buy	3,104,603 +383,552	+14%	+$909K	1.72%	11
2022 Q4	$5.06M	Buy	2,721,051 +1,327,029	+95%	+$2.26M	0.9%	16
2022 Q3	$2.56M	Buy	+1,394,022	New	+$2.92M	0.55%	15

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Madison Avenue Partners's OVID Position: Q3 2025 in Review

Madison Avenue Partners sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 1,311,362 shares — an estimated $433K sold.

Madison Avenue Partners first reported a position in OVID in Q3 2022 and held it in 12 quarters. The position peaked at $14M in Q3 2023. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

Madison Avenue Partners reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
Madison Avenue Partners sold 1,311,362 Ovid Therapeutics shares in Q3 2025, an estimated $433K.
Madison Avenue Partners first reported a position in Ovid Therapeutics in Q3 2022 and held it in 12 quarters.
Madison Avenue Partners's Ovid Therapeutics position peaked at $14M in Q3 2023.
81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on Madison Avenue Partners's 13F filing for Q3 2025, filed 14 Nov 2025.